Your browser doesn't support javascript.
loading
Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.
Vermersch, Patrick; Oreja-Guevara, Celia; Siva, Aksel; Van Wijmeersch, Bart; Wiendl, Heinz; Wuerfel, Jens; Buffels, Regine; Kadner, Karen; Kuenzel, Thomas; Comi, Giancarlo.
Afiliação
  • Vermersch P; Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France.
  • Oreja-Guevara C; Hospital Clínico San Carlos, Madrid, Spain.
  • Siva A; Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey.
  • Van Wijmeersch B; University MS Centre, Pelt, Hasselt University, Hasselt, Belgium.
  • Wiendl H; Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.
  • Wuerfel J; Medical Image Analysis Center (MIAC AG), Department of Biomedical Engineering, University of Basel, Basel, Switzerland.
  • Buffels R; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Kadner K; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Kuenzel T; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Comi G; Vita-Salute San Raffaele University, Milan Casa di Cura del Policlinico, Milan, Italy.
Eur J Neurol ; 29(3): 790-801, 2022 03.
Article em En | MEDLINE | ID: mdl-34748672

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Esclerose Múltipla Tipo de estudo: Clinical_trials / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Recidivante-Remitente / Esclerose Múltipla Tipo de estudo: Clinical_trials / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article